I’d snap up this growth stock at 29p without hesitation!

This writer shines a light on one growth stock in the small-cap space whose price has nearly doubled in the past year but still looks good value.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I believe there are excellent opportunities in small-cap growth stocks today, particularly with multiple interest rate cuts on the horizon. One such opportunity is hVIVO (LSE: HVO), which provided a bullish H1 trading update yesterday (17 July)

In response, the stock rose 5% to 29p, but I reckon it’s set for further gains in the years ahead.

Record revenue growth

AIM-listed hVIVO is a specialist contract research organisation (CRO) and world leader in testing infectious disease products using human challenge clinical trials. These are where healthy volunteers are infected with pathogens to test diseases and potential treatments. This approach can save time and money for its customers (pharmaceutical firms) when conducting trials.

The company recruits volunteers through its own FluCamp platform then runs the trials at its designated quarantine facilities. It also offers standalone laboratory support and clinical consultancy services.

In the six months to the end of June, the firm’s revenue jumped 30.6% year on year to a record £35.6m. Its EBITDA profit margin improved from 19.1% in H1 2023 to approximately 24%. This was driven by enhanced operational efficiencies from running multiple quarantine facilities.

Meanwhile, its cash position increased to £37.1m from £31.3m the year before. The company has no debt.

For the full year, it reaffirmed revenue guidance of £62m (10.7% growth) and said EBITDA margins were anticipated to be at the upper end of market expectations.

We have full visibility over our expected 2024 revenues and continue to deliver on our sustainable growth strategy. The orderbook remains strong in spite of record revenue delivery in H1 2024. The recent Omicron characterisation study contract and the award of our largest field study to date are two key sales highlights for H1 2024. In addition, the current sales pipeline includes several advanced stage opportunities that we expect to convert in the coming months. 

Yamin ‘Mo’ Khan, CEO of hVIVO, H1 2024 trading update

Risk and competition

One risk here is that human challenge studies are subject to stringent regulations. Any changes in such requirements or non-compliance could lead to delays, increased costs, or the halting of studies.

Plus, there are other firms around the world that compete with hVIVO in attracting contracts for clinical trials related to infectious diseases and respiratory illnesses. So it isn’t the only show in town.

New state-of-the-art facility

Despite these risks, things look very bright here. The company has just opened the world’s largest human challenge trial unit in London’s Canary Wharf. This will enable hVIVO to broaden its offerings to include new pathogen models and other services.

This new facility is expected to provide the capacity for £100m in revenue by 2028. With an assumed EBITDA margin of 24%, this gives a price-to-EBITDA ratio of around 8.5 for 2028. That’s attractive, assuming everything goes to plan, which isn’t guaranteed but looks increasingly likely.

For this year, the stock is trading on a forward price-to-earnings (P/E) multiple of 21. Again, I think that’s decent value for a fast-growing firm.

Finally, the stock is still 22% lower than a high of 38p reached back in 2021. I wouldn’t be surprised to see this one go on to hit new highs. If I didn’t already own the stock, I’d add it to my portfolio at 29p right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in hVIVO Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »

Investing Articles

The JD Sports Fashion share price has just plunged another 16%! Buy or sell?

Harvey Jones is reeling after another sharp drop in the JD Sports Fashion share price. Should he seize the chance…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

This once-great FTSE 250 UK fashion retailer is down 47%, so is it time for me to buy?

A formerly iconic UK fashion brand, this FTSE 250 firm has fallen out of favour. But it has a new…

Read more »

Investing Articles

Nvidia share price dips despite strong Q3 results. What can we expect now?

Despite posting strong Q3 results after yesterday's market close, the Nvidia share price slipped 2.5% in aftermarket trading. Mark Hartley…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

An outstanding interim report sends the Halma share price surging 10%

News of 13% revenue growth and a 17% increase in earnings per share has the Halma share price rising. And…

Read more »